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The generation and maintenance of memory 
T cells is central to the development of protective 
immunity, as characterized by a rapid and vig-
orous response after the encounter with a given 
pathogen or antigen (1, 2). Despite the com-
plexity of the memory T cell populations, 
  recent studies in both mice and humans indicate 
that the memory T cell pool is composed of 
two main compartments, central memory and 
eff  ector memory T cells (TCM and TEM, respec-
tively), which are characterized by distinct 
homing capacities and eff  ector functions (3, 4). 
Through their expression of CC chemokine 
receptor (CCR) 7 and CD62L, TCM preferen-
tially home to T cell areas of secondary lym-
phoid organs and display few immediate 
eff  ector functions; however, they readily pro-
liferate and diff  erentiate to eff  ector cells in 
  response to antigenic stimulation. TEM that 
have lost the constitutive expression of CCR7 
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The molecular events involved in the establishment and maintenance of CD4+ central 
memory and effector memory T cells (TCM and TEM, respectively) are poorly understood. 
In this study, we demonstrate that ex vivo isolated TCM are more resistant to both spontaneous 
and Fas-induced apoptosis than TEM and have an increased capacity to proliferate 
and persist in vitro. Using global gene expression profi  ling, single cell proteomics, and 
  functional assays, we show that the survival of CD4+ TCM depends, at least in part, on the 
activation and phosphorylation of signal transducer and activator of transcription 5a 
(STAT5a) and forkhead box O3a (FOXO3a). TCM showed a signifi  cant increase in the levels 
of phosphorylation of STAT5a compared with TEM in response to both IL-2 (P < 0.04) and 
IL-7 (P < 0.002); the latter is well known for its capacity to enhance T cell survival. 
  Moreover, ex vivo TCM express higher levels of the transcriptionally inactive phosphorylated 
forms of FOXO3a and concomitantly lower levels of the proapoptotic FOXO3a target, Bim. 
Experiments aimed at blocking FOXO3a phosphorylation confi  rmed the role of this 
  phosphoprotein in protecting TCM from apoptosis. Our results provide, for the fi  rst time in 
humans, an insight into molecular mechanisms that could be responsible for the longevity 
and persistence of CD4+ TCM. CORRESPONDENCE
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  express tissue-homing receptors associated with infl  ammation 
and more readily display eff   ector functions. The current 
model proposes that upon reinfection, TEM rapidly con-
strain pathogen invasion in infl   amed peripheral tissues, 
whereas TCM are rapidly activated by DCs in secondary lym-
phoid organs and generate successive waves of eff  ectors able 
to completely eliminate the pathogen (2).
Experiments performed in mouse models suggest that 
TCM have a better capacity to reconstitute the memory T cell 
pool and to mediate protective immunity than TEM because 
of their greater capacity to proliferate and persist in vivo 
(5, 6). Studies in primate models show that induction of cen-
tral memory CD4+ T cells after SIV challenge correlates with 
prolonged survival (7), thereby highlighting the importance 
of gaining a better understanding of the mechanisms under-
lying TCM induction and persistence for successful vaccine 
  development. The molecular mechanisms underlying the 
persistence of these cell subsets are still unknown, and it 
  remains unclear whether TCM and TEM use the same mecha-
nisms to persist in the host. The long-term maintenance of 
memory T cells relies on the survival of individual cells and 
their level of homeostatic cell division to compensate for 
their gradual attrition through apoptosis (2, 8). Using in vivo 
labeling with deuterated glucose to measure the turnover of 
distinct subsets of CD4+ T cells in healthy humans, Macallan 
et al. have shown that TEM have a more rapid turnover than 
TCM, suggesting that TEM are being replaced at a faster rate 
than TCM (9). These diff  erent turnover rates might be attribu-
ted to intrinsic diff  erences in their susceptibility to apoptosis, 
although this has never been directly addressed.
The nature of the signals that ensure the persistence of 
TCM is under intense investigation. Results obtained in mouse 
Figure 1.  Functional and phenotypical characterization of CD4+ 
TCM and TEM. (A) CD45RA, CD27, and CCR7 labeling profi  le and gating 
strategy for naive, TCM, and TEM. Percentages obtained for each population 
are indicated. The purity of sorted cells was consistently >95%. (B) Per-
forin and Gr-B expression in ex vivo TCM and TEM subsets. Perforin and 
Gr-B expression were assayed by intracellular staining. The percentages 
of TCM and TEM expressing perforin and Gr-B are indicated in each quadrant. 
SSC, side scatter. (C) Rab-27a protein levels in ex vivo sorted TCM and TEM 
subsets. Similar results were obtained in three independent experiments. 
(D) Susceptibility of TCM and TEM to Fas-induced apoptosis. TCM and TEM 
were sorted by fl  ow cytometry and treated with 1.25 μg/ml of the anti-
Fas antibody CH11 or 100 μg/ml etoposide for 24 h. The percentage of 
apoptotic cells was assessed by fl  ow cytometry using Annexin V labeling. 
The results are depicted as a percentage of apoptotic cells ± SD of three 
independent experiments. (E) Proliferation and persistence of purifi  ed TCM 
and TEM. Sorted TCM and TEM were co-cultured with mDCs in the presence 
of superantigen (SEA) for 15 d. After 1–15 d, the proportion of proliferat-
ing cells was assessed by staining of anti-TCRVβ22, as Vβ22 is known to 
be a highly SEA-reactive Vβ. Results are represented as the percentage 
of Vβ22-positive cells.JEM VOL. 204, January 22, 2007  81
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models have suggested that signaling through TCR and 
γ chain cytokine receptors is required for long-term survival 
of memory T cells (10–13). For example, memory CD4 cells 
persisted for extended periods upon adoptive transfer into in-
tact or lymphopenic recipients but not in IL-7−/− mice (11). 
Moreover, Kassiotis et al. have demonstrated that the ho-
meostatic expansion capacity of both CD4+ naive and mem-
ory cells is dependent on the expression levels of TCR and 
CD5, a negative regulator of TCR signaling (13). It is possi-
ble that TCM and TEM respond distinctively to these signals, 
thereby infl   uencing their long-term maintenance. In this 
study, we have used gene and protein expression profi  ling 
and functional assays of human CD4+ T EM and TCM to 
  identify the mechanisms underlying their maintenance. Our 
results provide a molecular basis for the capacity of CD4+ 
TCM to resist apoptosis and to persist in a stable manner in the 
host, thereby conferring long-term protective immunity 
against reinfection.
RESULTS
Functional and phenotypic characterization 
of CD4+ TCM and TEM
Memory T cell subsets were sorted by fl  ow cytometry from 
whole PBMCs isolated from 13 healthy donors based on 
CD45RA, CD27, and CCR7 expression. Naive cells are 
characterized as CD45RA+, CD27+, and CCR7+; TCM have 
the phenotypes CD45RA−, CD27+, and CCR7+; TEM are 
defi  ned by the lack of expression of these three markers 
(CD45RA−, CD27−, and CCR7−) (Fig. 1 A) (14); and tran-
sitory memory T cells (TTM) are characterized as CD45RA−, 
CD27+, and CCR7− (TTM; Fig. 1 A). All TCM (>95%) 
  expressed CD28, CD62L, and CD95. TEM were also homo-
geneously CD28+ and CD95+, albeit only 30–40% expressed 
CD62L (unpublished data). As expected, the ex vivo sorted 
TEM subpopulation expressed the eff  ector molecules gran-
zyme B and perforin, whereas these two molecules were 
  undetectable in TCM (Fig. 1 B). TEM also showed higher 
Figure 2.  Gene expression array analysis of ex vivo CD4+ TCM 
and TEM. (A) PCA. TCM (blue) separate well from TEM (red) in this three-
dimensional projection of the fi  rst three principal components. (B) Two-
way hierarchical clustering of CD4+ TCM and TEM expression profi  les. The far 
left column represents sample labels, with TCM donors shown as green 
squares, and TEM donors shown as orange squares. Each additional column 
represents a different gene; green indicates lower than median expression 
(down-regulation) and red indicates higher than median expression 
(up-regulation). The results of the two-dimensional hierarchical clustering 
of genes and samples (Pearson correlation similarity measure) are shown 
as horizontal and vertical dendrograms.82  MAINTENANCE OF HUMAN CENTRAL MEMORY CELLS | Riou et al.
(threefold) expression levels of Rab27a, a molecule  involved 
in degranulation and eff  ector function (15), than TCM (Fig. 1 C). 
Collectively, these results show that TEM are functionally and 
phenotypically more diff  erentiated than TCM.
CD4+ TCM are resistant to Fas-induced apoptosis and show 
enhanced proliferation capacity after stimulation with 
mature DCs (mDCs)
TCM are long lived and should thus be resistant to cell death 
signals. We therefore determined their sensitivity to apoptosis 
as compared with the shorter-lived TEM. Sorted TCM and 
TEM were cultured in the presence or absence of anti-Fas 
  antibody or etoposide for 24 h (n = 3). Annexin V labeling 
showed a signifi  cant diff  erence (P ≤ 0.007) in the capacity of 
TCM to resist Fas-mediated apoptosis as compared with TEM 
(Fig. 1 D). Of note, TCM are less prone to undergo spontane-
ous apoptosis (i.e., without any apoptotic inducers; P ≤ 0.02) 
than the TEM subset (Fig. 1 D). Moreover, in response to 
  etoposide, used as a nonspecifi  c apoptotic inducer, both TCM 
and TEM present similar sensitivity to apoptosis, thereby con-
fi  rming that the apoptotic machinery is intact in both cell 
types. We also determined the capacity of purifi  ed TCM and 
TEM to proliferate and persist in a 15-d culture assay after 
stimulation with staphylococcal enterotoxin superantigen 
(SEA)–pulsed mDCs. Proliferation was determined by quan-
tifying the expansion of the SEA-responsive TCRVβ22+ T 
cells. TCM present a better expansion potential and can persist 
longer than TEM, as demonstrated by a 10-fold increase in the 
absolute number of SEA-responsive TCRVβ22+ T cells in a 
15-d culture period (Fig. 1 E). Similar data were also gener-
ated using carboxyfl   uorescein diacetate succinimidyl ester, 
whereby TCM undergo several more rounds of proliferation 
when compared with TEM (unpublished data). Collectively, 
these results demonstrate that CD4+ TCM and TEM subsets 
exhibit diff  erent capacities to proliferate, persist, and undergo 
both spontaneous and Fas-induced apoptosis. These  observations 
Table I.  Differential expression of apoptosis-related genes in CD4+ TCM and TEM
Gene Name Accession 
number
p-valuea AVG FCb GO annotation
MAL T cell differentiation protein AK096093 0.02016 2.68 Proapoptotic
NGFRAP1 TNFRSF16-associated protein 1 CR593909 0.01641 2.55 Apoptosis
TNFRSF7 TNF receptor 7 CR624829 0.05641 2.37 Antiapoptotic
RELA Transcription factor NF-κB3 BC033522 0.01149 2.17 Antiapoptotic
TOSO Fas apoptotic inhibitory 
 molecule  3
NM_005449 0.07717 2.15 Antiapoptotic
PIM2 Pim-2 oncogene NM_006875 0.00954 1.93 Antiapoptotic
STAT5a Signal transducer and 
  activator of transcription
NM_003152 0.00543 1.72 Antiapoptotic
TNFRSF8 TNF receptor 8 AA147604 0.00511 1.51 Apoptosis
NOTCH3 In multiple clusters   0.01807 1.39 Antiapoptotic
TNF-a TNF member 2 BC028148 0.00372 1.38 Proapoptotic
E2F1 E2F transcription factor 1 BC050369 0.03707 1.38 Proapoptotic
TNFSF7 TNF ligand 7 BM464627 0.00271 1.37 Antiapoptotic
BIRC6 Apollon NM_016252 0.05593 1.34 Antiapoptotic
NGFR NGF receptor 16 AK125088 0.00767 1.34 Proapoptotic
CASP3 Caspase 3 NM_004346 0.05753 −1.33 Proapoptotic
TNFRSF1B TNF receptor 1B BC052977 0.02560 −1.39 Pro- or antiapoptotic
CASP8 Caspase 8 NM_033357 0.07165 −1.44 Proapoptotic
YARS Tyrosyl-tRNA 
 synthetase
AK125213 0.14050 −1.46 Proapoptotic
TGIF TGF-𝗃–induced factor NM_170695 0.07018 −1.59 Proapoptotic
IGFBP1 IGF factor binding protein 1 NM_004943 0.01336 −1.65 FOXO3a target
CLU Clusterin NM_203339 0.03113 −1.84 Proapoptotic
GZMB Granzyme B BQ052893 0.00231 −1.93 Proapoptotic
LGALS3 Galectin 3 AB209391 0.13870 −2.04 Proapoptotic
LGALS1 Galectin 1 BF570935 0.06611 −2.49 Proapoptotic
Signifi  cant genes were selected using an ANOVA t test (P < 0.05 or a fold change >1.7) and associated with an “apoptosis” GO annotation. Each gene on the arrays was 
spotted in duplicate to avoid false positive signals and to ensure the reproducibility of the data obtained. The fold change values were obtained from the average value 
of 13 independent hybridizations (AVG FC). The genes upregulated in TEM are bolded. A complete list of 270 genes is available in Table S1.
aThe p-values were determined by ANOVA, based on an F-test.
bFold change values were calculated from the average value of 13 independent hybridizations by subtracting the mean expression of the log2 ratio obtained in TCM from the 
log2 ratio obtained in TEM. That value was then converted into fold change.JEM VOL. 204, January 22, 2007  83
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led us to investigate the cell survival pathways responsible for 
that resistance to cell death in TCM and to characterize the 
diff  erences in these pathways between TCM and TEM.
Gene array analysis of TCM and TEM showed differences 
in gene expression associated with survival pathways
Sorted TCM and TEM were hybridized on two different 
chips: the custom immune array ( 3,000 unique transcripts) 
and a standardized 19K array ( 10,000 unique transcripts). 
The fi  rst level of analysis was performed by submitting 
26 samples (13 replicates per class) to unsupervised cluster ana-
lysis using principal component analysis (PCA). PCA enables 
the discrimination and visual clustering of two or more 
classes, where objects with similar patterns of gene expression 
are placed next to each other. As shown in Fig. 2 A, TCM and 
TEM visually segregate on a PCA plot. The distance separat-
ing TCM from TEM refl  ects diff  erences in overall gene expres-
sion between the two subsets. These diff  erences  were 
observed in most samples (10 out of 13 TCM clustered to-
gether with three outliers). Two-way hierarchical clustering 
of TCM and TEM (Fig. 2 B) further demonstrated that TCM 
and TEM subsets group apart and that the gene expression sig-
nature of TCM is considerably diff  erent than that of TEM.
Using single gene searches, we identifi  ed the genes that 
distinguished TCM from TEM. Genes selected using analysis of 
variance (ANOVA), where P < 0.05 or a fold change >1.7 
were considered signifi  cant. We identifi  ed >270 signifi  cant 
genes that distinguished both subsets. Within the selected 
genes, 6% were related to apoptosis, 9% to cell cycle, and 7% 
to signaling. These genes also encompassed biological func-
tions, including (a) homing and adhesion, (b) gene expression 
regulation, (c) immune response, and (d) transport. The 
complete list of genes can be found in Table S1 (available at 
http://www.jem.org/cgi/content/full/jem.20061681/DC1). 
Apoptosis-related genes displaying a diff  erent expression pro-
fi  le when comparing TCM with TEM are listed in Table I. TCM 
expressed higher levels of TOSO, CD27, STAT5a, PIM-2, 
RelA, and Birc6 (Bruce) mRNA, all belonging to distinct 
antiapoptotic pathways (16–20), than their TEM counterparts. 
In contrast, TEM showed higher levels of expression of genes 
  involved in the induction of apoptosis, including caspase-8 
and caspase-10, as well as several proteins endowed with a 
proapoptotic function, such as galectin-1 and galectin-3 (21), 
clusterin (22), YARS (23), and TGIF, a TGFβ-targeted gene 
(24). This expression profi  le suggested that TEM contain an 
active proapoptotic machinery, thereby explaining their en-
hanced susceptibility to cell death (Fig. 1 D). On the other 
hand, several genes that promote cell survival were selectively 
expressed at high levels in TCM, rendering them more resis-
tant to apoptosis. Of note, TTM (CD45RA−, CD27+, and 
CCR7−) display an intermediary phenotype between TCM 
and TEM. Indeed, their gene expression profi   les are very 
much comparable to TEM for certain genes (including CD62L, 
TOSO, and PIM2) and to TCM for other genes such as Bim, 
FasL, or IFN-γ (Fig. S1).
In the next set of experiments, we validated and detailed 
the gene array data by performing real-time RT-PCR on the 
same donor samples (Table II). The results showed a signifi  -
cant increase in the forkhead box O3a (FOXO3a) transcrip-
tional target proapoptotic genes, including Bim (25), FasL 
(26), and genes involved in cell cycle regulation, including 
GADD45a (27) and p130, a member of the retinoblastoma 
family (28) in the TEM subset. Furthermore, the RT-PCR 
data confi  rmed the up-regulation of the survival gene CD27 
and the antiapoptotic PIM-2 kinase, with the latter being 
regulated by the STAT5a cascade in TCM (29). These results 
validated our gene array data and further suggested the in-
volvement of STAT5a and FOXO3a signaling pathways in 
mediating the survival of TCM.
STAT5a signaling pathway is functionally 
up-regulated in TCM
STAT5a is a downstream eff  ector of γc cytokine receptors   
(30). We observed differential expressions of PIM-1 and 
PIM-2, two transcriptional targets of STAT5a in the ex vivo 
TCM subset. Indeed, TCM showed twofold higher expression 
of both PIM-1 and PIM-2 than TEM (n = 3; Fig. 3 A). 
  Because of the importance of the STAT5a pathway in the 
Table II.  Real-time RT-PCR of differential gene expressions in TCM and TEM
Gene Fold change 
TCM/TEM
a
Fold change 
TEM/TCM
a
Function Accession 
number
CD27 11.2 Antiapoptotic NM_001242
PIM-2 2.2 Antiapoptotic NM_006875
Bim 3.1 Proapoptotic NM_006538
FasL 7.3 Proapoptotic NM_000639
GADD45a 2.5 Cell cycle NM_001924
P130 RBL2 1.4 Cell cycle NM_005611
P27Kip 3.2 Cell cycle NM_004064
LKLF 4.1 Quiescence NM_016270
DUSP6 5.9 AKT inhibitor NM_001946
Total mRNA was isolated from TCM and TEM and analyzed by quantitative RT-PCR using a low density array. The bolded genes are up-regulated in TEM, whereas the other genes 
are up-regulated in TCM. Fold changes represent the changes in transcript level in TEM compared to TCM for two donors.
aFold change values were calculated from the average value of two independent experiments using log2 ratio values converted to fold change.84  MAINTENANCE OF HUMAN CENTRAL MEMORY CELLS | Riou et al.
regulation of T cell survival (30), we evaluated the ability of 
IL-2 and IL-7 to trigger the STAT5a signaling pathway in 
CD4+ T cell memory subsets. The phosphorylated form of 
STAT5a (Y694; pSTAT5a) was quantifi  ed by fl  ow cytometry. 
Basal pSTAT5a levels were similar in TCM and TEM (Fig. 3 B). 
All TCM and TEM up-regulated pSTAT5a in response to a 
brief IL-7 treatment (Fig. 3 B). However, the levels of 
pSTAT5a were signifi  cantly higher (30% ± 6.5; P < 0.002) 
in TCM as compared with TEM (Fig. 3 C). Treatment with 
IL-2 also induced diff  erential pSTAT5a levels (P < 0.04) 
  between TCM and TEM. Indeed, 90–100% of TCM showed 
a  phosphorylated STAT5a form, compared with 50–60% 
  observed in TEM. Of note, TEM present a bimodal distribution 
of pSTAT5a in response to IL-2, indicating that TEM are 
  heterogeneous in terms of response to IL-2.
The diff  erences in pSTAT5a levels were not caused by 
diff  erences in the levels of expression of IL-2 or IL-7 recep-
tors. Indeed, the proportion of cells expressing CD127 
(IL-7Rα), CD25 (IL-2Rα), and CD132 (γc chain) on TCM 
were comparable to those on TEM (Fig. 3 D). Of note, CD122 
(IL-2Rβ) was undetectable on ex vivo TCM and TEM (unpub-
lished data). Although IL-2R is expressed on  20% of TCM 
as assessed by cytometry, 100% of these cells are able to phos-
phorylate STAT5a in response to IL-2. This suggests that 
TCM express levels of IL-2R below the detection limits of 
our assay that are suffi   cient to induce STAT5a signaling in 
  response to IL-2. Collectively, these results indicate that the 
STAT5a pathway, as shown by the levels of pSTAT5a and its 
downstream eff  ectors (PIM-1 and PIM-2), is diff  erentially 
regulated between TCM and TEM. The observed diff  erences 
suggest that TCM display an enhanced capacity to mobilize 
the STAT5a pathway for their survival as compared with 
TEM. These results complement previous data obtained by 
Willinger et al., who reported that CD8+ T CM present a 
higher ability to phosphorylate STAT5a in response to both 
IL-2 and IL-7 than CD8+ TEM (31).
Regulation of the FOXO3a pathway in memory 
CD4+ T cell subsets
FOXO3a transcriptional activity is regulated through direct 
phosphorylation. Once phosphorylated, FOXO3a is ex-
cluded from the nucleus and thus becomes transcriptionally 
inactive. FOXO3a controls the expression of several genes 
implicated in apoptosis and cell cycle regulation, including 
FasL, Bim, Gadd45a, p27kip, and p130 (32, 33). Our gene 
array analysis and RT-PCR data suggested the specifi  c in-
volvement of the FOXO3a pathway in TCM survival (Table 
II). Therefore, we analyzed the phosphorylation status of 
FOXO3a in TCM and TEM. We observed that the levels of 
pFOXO3a (S315, S253, and T32) were reproducibly (n = 5) 
more than twofold higher in ex vivo TCM as compared 
with TEM. It is worth noting that expression levels of total 
FOXO3a remained similar in the two memory subsets (Fig. 
4 A, top). We then determined whether the observed reduc-
tion in FOXO3a phosphorylation levels seen in TEM was 
  associated with increased levels of FOXO3a target proteins. 
Our results show that TEM expressed threefold higher levels 
of Bim and p130 proteins and a 1.7-fold higher expression of 
GADD45a when compared with the TCM compartment 
Figure 3.  STAT5a signaling pathway is functionally up-regulated 
in TCM. (A) PIM-1 and PIM-2 protein levels in ex vivo sorted TCM and TEM 
subsets. Similar results were obtained in three independent experiments. 
(B–D) PBMCs from healthy donors were treated with 100 U/ml IL-2 or 
10 ng/ml IL-7 for 15 min at 37°C. Cells were labeled with antibodies to 
CD4, CD27, CCR7, CD45RA, and pSTAT5a. (B) Representative example of 
pSTAT5a expression levels. TCM-gated cells are represented in light gray, 
and TEM-gated cells are represented in dark gray. (C) Mean fl  uorescence 
intensity (MFI) of pSTAT5a level of expression measured in response to 
IL-2 or IL-7 in TCM and TEM (n = 4). Mean pSTAT5a signal values are repre-
sented by black bars. p-values (determined by the two-tailed t test) are 
shown. (D) Expression level of CD25, CD132, and CD127 in ex vivo TCM 
and TEM. PBMCs were labeled with antibodies to CD4, CD27, CCR7, and 
CD45RA to identify T cells subsets in conjunction with anti-CD127– or 
anti-CD25–specifi  c antibodies. The results represent the proportions of 
CD127- and CD25-positive cells on TCM- and TEM-gated T cells (the per-
centage of positive cells ± SD of fi  ve experiments).JEM VOL. 204, January 22, 2007  85
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(Fig. 4 A,   bottom). FasL, whose mRNA was clearly ex-
pressed at higher levels in TEM than in TCM (Table II), was 
undetectable in ex vivo TCM and TEM when assayed by West-
ern blot and cytometry (unpublished data). However, upon 
T cell activation induced by PMA and ionomycine, FasL was 
selectively up-regulated in TEM (in  30% of the TEM subset), 
whereas it remained undetectable in TCM (Fig. 4 B). Collec-
tively, our data show that a high expression of pFOXO3a 
observed in TCM is associated with the shutdown of Bim, 
Gadd45a, and p130 proteins, thereby favoring their long-
term survival.
Blocking of AKT and I𝗋B kinase (IKK) activity prevents 
FOXO3a phosphorylation, leading to TCM cell death
Several kinases, including AKT, IKK-β, casein kinase 1, and 
DYRK1A, have been reported to directly phosphorylate 
FOXO3a (34, 35). To identify the kinases involved in the 
phosphorylation of FOXO3a in TCM, we analyzed FOXO3a 
phosphorylation in CD4+ T cells (CD4+ T cells were used 
because of the limiting amounts of TCM and TEM obtained 
  after sorting) after treatment with specifi  c kinase inhibitors. 
We used the pharmacological kinase inhibitors AKT-IV 
and wedelolactone, which inhibit AKT and IKK activities, 
  respectively. We also tested two other kinase inhibitors: 
STO-609, specifi  c for CamKK and described as an upstream 
mediator of AKT (36), and the MEK1/2 inhibitor U0126, 
used as an irrelevant kinase inhibitor. The results (Fig. 5 A) 
clearly showed that treatment with the AKT and IKK inhibi-
tors led to a specifi  c and signifi  cant reduction in the levels 
of pFOXO3a (S253). The expression levels of pFOXO3a 
(S253) in CD4+ T cells were eightfold lower in the presence 
of the AKT inhibitor and 4.5-fold lower in the presence of 
the IKK inhibitor as compared with untreated cells (Fig. 5 A). 
It is worth noting that, in total CD4+ T cells, pFOXO3a 
(S315) is barely detectable (unpublished data). FOXO3a 
can induce apoptosis through the up- regulation of proapop-
totic genes (25, 34, 37, 38). To confi  rm the importance of 
the phosphorylation of FOXO3a in memory T cell survival, 
purifi  ed CD4+ T cells were treated with diff  erent kinase in-
hibitors, and apoptosis was assessed using Annexin V labeling. 
Fig. 5 B shows that the proportion of Annexin V+ cells is 
  increased in a dose-dependant fashion after exposing CD4+ 
T cells to AKT or IKK inhibitors. Moreover, we observed a 
signifi  cant up-regulation of the levels of the proapoptotic 
molecule Bim, known to be a FOXO3a target, in cells treated 
with AKT or IKK inhibitors (three- and eightfold, respec-
tively; Fig. 5 C). Of note, the AKT and IKK inhibitors did 
not change the levels of FasL expression when assayed by 
Western blot or cytometry (unpublished data). These results 
indicated that the dephosphorylation of FOXO3a in CD4+ 
T cells was associated with Bim up-regulation and apoptosis. 
None of the other kinase inhibitors tested induced apoptosis 
in CD4+ T cells (Fig. 5 B), even when used at much higher 
concentrations (not depicted). Collectively, these results 
show that among the kinase inhibitors tested, only those able 
of inducing FOXO3a dephosphorylation have the capacity 
Figure 4.  Regulation of the FOXO3a pathway in memory CD4+ 
T cell subsets. (A) FOXO3a, pFOXO3a (S315, S253, or T32), Bim, p130, and 
Gadd45a protein levels in ex vivo sorted TCM and TEM. (B) Expression of 
FasL on activated TCM (gray) and TEM (black). PBMCs were activated with 
10 ng/ml PMA and 500 ng/ml ionomycine for 24 h. Intracellular staining 
was performed using CD4, CD27, CD45RA, CCR7, and FasL antibodies. The 
percentages of FasL-positive cells for each subset are indicated. MFI 
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to induce CD4+ T cell apoptosis. It is thus likely that activated 
AKT and IKK promote CD4+ cell survival in part by phos-
phorylating FOXO3a, thereby repressing its transcriptional 
activity and leading to the down-regulation of the proapop-
totic molecule Bim.
To assess the importance of AKT and IKK in the survival 
of memory cells, we evaluated the expression of the phos-
phorylated forms of these proteins in TCM and TEM subsets. 
First, pIKKα∕β expression was assayed in ex vivo sorted TCM 
and TEM. Although pIKKα∕β was expressed in TCM, it was 
undetectable in TEM (Fig. 5 D). Second, because the phos-
phorylated form of AKT was undetectable by Western blot on 
ex vivo sorted cells, we performed a Phosfl  ow analysis on 
PBMCs treated with H2O2 (which is known to induce phos-
phorylation of AKT). The results showed that the induction 
of pAKT (S473) was higher in TCM than TEM in response to 
H2O2 (Fig. 5 E and Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20061681/DC1). More importantly, in 
response to CD28 triggering, TCM presented a modest ( 20%) 
but consistent increase (P < 0.007) in AKT phosphorylation 
as compared with the TEM (Fig. 5 E). These results suggest that 
in resting TCM, the constitutive activation of IKKα∕β could 
lead to FOXO3a phosphorylation. Moreover, CD28 trigger-
ing leads to higher levels of pAKT in TCM and could also pro-
mote FOXO3a phosphorylation. Collectively, these results 
suggest that the phosphorylation levels of FOXO3a in TCM 
can be maintained, both in their resting state and upon CD28 
triggering, through the activation of IKK and AKT, respec-
tively, thereby promoting TCM survival.
The corollary of the results (Fig. 5) is that the lack of 
FOXO3a phosphorylation could render TCM susceptible to 
signals inducing cell death. To determine the implication of 
Figure 5.  AKT and IKK mediate FOXO3a phosphorylation and 
  survival in CD4 T cells. (A) Regulation of FOXO3a phosphorylation. 
 Purifi  ed CD4+ T cells were pretreated for 1 h with kinase inhibitors (10 μM 
AKT-VI, an AKT inhibitor; 5 μg/ml STO-609, a CamKK inhibitor; 100 μM 
wedelolactone, an IKK inhibitor; and 50 μM U0126, an MEK1/2 inhibitor). 
pFOXO3a (S253) was assessed. The results are representative of two inde-
pendent experiments. (B) CD4+ T cell susceptibility to apoptosis induced 
upon treatment with specifi  c kinase inhibitors. CD4+ T cells were cultured 
in the presence of kinase inhibitors for 24 h (100 μM U0126 and 10 μg/ml 
STO-609, and wedelolactone and AKT-IV as indicated). After 24 h, the 
proportion of Annexin V+, propidium iodide+ cells was quantifi  ed by 
fl  ow cytometry. The results are depicted as a percentage of apoptotic 
cells within the total population and are representative of two independ-
ent experiments. (C) Bim expression levels in response to AKT and IKK 
inhibitors. CD4+ T cells were treated with 1.6 μM AKT-IV or 100 μM 
wedelolactone for 24 h. Cells were analyzed by Western blotting using 
Bim specifi  c antibodies. (D and E) Regulation of AKT and IKK phosphoryla-
tion in CD4+ memory subsets. (D) pIKKαβ (S176/180) protein levels in 
ex vivo sorted TCM and TEM. Prolonged exposure did not reveal any pIKK 
signal in TEM. Similar results were obtained in three independent experi-
ments. (E) PBMCs from healthy donors were treated with 5 mM H2O2 
or 2 μg/ml Ig–cross-linked CD28 for 15 min at 37°C and labeled with 
CD4-, CD27-, CD45RA-, and pAKT (S473)-specifi  c antibodies. The levels 
of pAKT were assessed by fl  ow cytometry in TCM- and TEM-gated cell 
  subsets. The results are represented as the mean fold increase ± SD of 
fi  ve independent experiments, calculated as follows: (MFI of stimulated 
cells/MFI of unstimulated cells). p-values (determined by the two-tailed 
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the AKT and IKK signaling pathways in the survival of TCM, 
we sorted TCM and TEM and exposed them to AKT or IKK 
inhibitors at their IC50 (1.6 μM AKT-IV and 100 μM wede-
lolactone). After 24 h of treatment, the proportion of apop-
totic cells was quantifi  ed using Annexin V labeling (Fig. 6, 
top). The treatment of TCM with the IKK inhibitor resulted 
in an eightfold increase in Annexin V+ cells, whereas only a 
twofold increase was observed in TEM, all relative to untreated 
cells (n = 2; Fig. 6, bottom). Similar results were also  observed 
when these subsets were exposed to the AKT inhibitor (Fig. 6). 
Experiments aimed at blocking FasL triggering, using Fas-Fc 
chimera, in response to AKT and IKK inhibitor–induced 
apoptosis did not prevent TCM cell death (unpublished data). 
These results indicate that abrogating the AKT and/or IKK 
survival pathways leads to apoptosis to a greater extent in 
TCM as compared with TEM, confi  rming that TCM are primar-
ily more dependent on these pathways for their survival. 
Moreover, the ability of AKT and IKK inhibitors to up-
  regulate Bim levels of expression (Fig. 5 C) without aff  ecting 
FasL expression suggests that cell death induced by these 
  kinase inhibitors could be achieved in part through FOXO3a 
dephosphorylation and the subsequent increased expression 
of the proapoptotic molecule Bim.
TCR and cytokine triggering phosphorylate distinct sites 
on FOXO3a
To identify the signals that trigger FOXO3a phosphorylation 
in CD4+ T cells, we quantifi  ed the levels of pFOXO3a (S253, 
S315, and T32) in response to CD3 and/or CD28 cross-
linking, IL-2, IL-7, IFN-γ, and PMA treatment. pFOXO3a 
(S253) was easily detectable in ex vivo CD4+ T cells, and 
none of the tested stimuli induced considerable changes in the 
phosphorylation status of this protein (Fig. 7 A). In contrast, 
FOXO3a phosphorylation on S315 was signifi  cantly induced 
in response to CD3 + CD28 triggering. It is worth noting 
that CD3 or CD28 triggering alone did not lead to FOXO3a 
phosphorylation (S315), indicating that the synergy of both 
signals is essential for FOXO3a phosphorylation at S315 
(lanes 2, 3, and 4; Fig. 7 A, top). None of the other tested in-
ducers (including γc cytokines) led to FOXO3a (S315) phos-
phorylation. Interestingly, the levels of pFOXO3a at T32 
were drastically increased when CD4+ T cells were treated 
with IL-7 or IL-2. No induction of pFOXO3a (T32) was 
  observed when cells were triggered with CD3 + CD28 (Fig. 
7 B). Collectively, these results indicate that TCR and γc 
cytokines IL-2 and IL-7 triggering induce specifi  c FOXO3a 
phosphorylation at distinct sites (S315 and T32, respectively), 
Figure 6.  Susceptibility of TCM and TEM to apoptosis induced by 
kinase inhibitors. Sorted TCM and TEM were cultured with or without AKT 
and IKK inhibitors as indicated. After 24 h, the percentage of apoptotic 
cells was quantified by Annexin V–FITC labeling. (top) Results from a 
  representative individual. Histogram plots show the percentage of Annexin 
V+ cells in TCM and TEM after a 24-h exposure to AKT or IKK inhibitors. 
The dashed lines correspond to untreated cells, and the plain lines corre-
spond to cells treated with kinase inhibitors. (bottom) Bar graph represen-
tation of the fold increase of apoptosis in TCM and TEM in response to IKK 
or AKT inhibitors. The fold increase of apoptosis is calculated as the per-
centage of apoptotic cells in treated cells divided by the percentage of 
apoptotic cells in untreated cells. Similar results were obtained in two 
independent experiments.
Figure 7.  FOXO3a phosphorylation is dependent on TCR and 
  cytokine engagement. (A) CD4+ T cells were cultured in the presence 
of 2 μg/ml CD3, 2 μg/ml CD28, CD3 + CD28, 100 U/ml IL-2, 10 ng/ml 
IL-7, 50 μg/ml IFN-γ, or 50 ng/ml PMA for 15 min and analyzed by West-
ern blotting for pFOXO3a (S315 and S253) expression levels. (B) CD4+ 
T cells were cultured in the presence of 100 U/ml IL-2, 10 ng/ml IL-7, or 
CD3 + CD28 for 30 min and analyzed by Western blotting for pFOXO3a 
(T32) expression levels. The results are representative of two indepen-
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suggesting that the convergence of both signals is required 
to induce optimal FOXO3a phosphorylation and the subse-
quent inhibition of its transcriptional up-regulation of the 
proapoptotic machinery.
D  I  S  C  U  S  S  I  O  N 
The involvement of TCR/ligand signaling in the generation 
and long-term survival of CD4+ TCM has been a matter of 
much debate. Indeed, although the persistence of both CD8 
and CD4+ T cells seems to occur in the absence of MHC 
antigen (39, 40), it has been demonstrated that repeated 
  exposure to native or cross-reactive epitopes improves memory 
T cell survival and function (12, 13). Moreover, cytokines 
such as IL-2 and IL-7 have also been shown to enhance 
CD4+ TCM survival, although the exact mechanisms leading 
to this function have yet to be identifi  ed (10, 11, 41). In this 
paper, we focus on ex vivo polyclonal TCM and TEM to iden-
tify the molecular pathways involved in the maintenance and 
survival of memory cells. Using highly purifi  ed subsets of 
TCM and TEM obtained by multiparametric cell sorting, we 
propose that two converging specifi  c signaling pathways are 
involved in providing TCM with the capacity to survive and 
resist apoptotic signals. Our results indicate that TCR and γc 
cytokine (IL-2 and IL-7) signaling induces FOXO3a phos-
phorylation, thereby preventing the transcription of pro-
apoptotic molecules such as FasL and Bim; moreover IL-2 
and IL-7 allow the activation of STAT5a and the concomi-
tant induction of several antiapoptotic molecules (PIM-1 
and PIM-2). In contrast, protective functions associated with 
these pathways are less effi   cient in TEM (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20061681/DC1).
In this study, we fi  rst examined the properties of TCM 
and TEM, based on a previously established classifi  cation of 
CD4+ T cell subsets (3, 4), using transcriptional profi  ling by 
cDNA microarrays. Our results show that these two subsets 
exhibit considerable diff  erences at the gene expression level, 
including several genes endowed with apoptotic functions. 
Other reports have investigated the gene expression profi  les 
of human TCM and TEM in both CD8+ (31, 42) and CD4+ 
populations (43, 44). For the CD8+ T cell subsets, TCM 
clearly cluster apart from TEM (31). According to the litera-
ture and our data, CD4+ TCM and TEM also display diff  erent 
gene expression profi  les. Despite the use of diff  erent DNA 
chips and diff   erent surface markers to distinguish TCM 
(CD45RO+ CD27+ [44], CD45RO+ CCR7+ [43], or 
CD45RA− CD27+ CCR7+ in the present study) from TEM, 
several common genes were shown to be up-regulated in 
TEM (ID2, CD63, CCL4, Grz-A, and DUSP6), whereas 
others were up-regulated in TCM ( MAL,  CD62L, and 
CD27) (Tables I and II; and Table S1) (43, 44). This indi-
cates that human TCM display a specifi  c gene signature that 
distinguished them from TEM. Among the genes diff  eren-
tially expressed by TCM and TEM, we consistently found that 
TCM express lower levels of Bim, FasL, Gadd45a, and p130, 
genes that are all described as FOXO3a target genes (Tables 
I and II) (25–28).
FOXO3a activity is regulated through phosphorylation. 
In its phosphorylated form, FOXO3a is retained in the cyto-
plasm and is functionally inactive. Once dephosphorylated, it 
is translocated into the nucleus and leads to the expression of 
proapoptotic targeted genes such as FasL and Bim (33). Sev-
eral reports have shown the role of FOXO3a-induced tran-
scriptional activation of FasL or Bim in the active induction 
of apoptosis in diff  erent models. These include, for Bim, 
  cytokine deprivation in lymphoid cells (38) and paclitaxel 
  induction of apoptosis in breast cancer cells (45), and Jurkat 
cells and neutrophils for FasL (37, 46). Of note, none of those 
reports has investigated the synergistic role of both molecules 
in FOXO3a-mediated apoptosis. Using mutant forms of 
FOXO3a, Brunet et al. demonstrated that the localization of 
FOXO3a is not dependent on a specifi  c phosphorylation site 
and that increased FOXO3a phosphorylation enhanced its 
retention in the cytosol. Higher levels of pFOXO3a lead to 
its increased retention in the cytoplasm (37).
Our results indicate that TCM express a high level of 
pFOXO3a for most FOXO3a putative phospho-sites, including 
T32, S253, and S315. In addition, ex vivo TCM present 
  reduced levels of Bim. On the other hand, FOXO3a is signi-
fi  cantly less phosphorylated in TEM, thereby promoting its 
activation. Indeed, we consistently observed a signifi  cant up-
regulation of FOXO3a transcriptional targets in TEM: Bim, 
p130, and GADD45a at both mRNA and protein levels. The 
increased presence of pFOXO3a, primarily in TCM (which 
are more resistant to apoptosis than TEM), strongly suggests 
that elevated levels of pFOXO3a could account, in part, for 
this subset’s resistance to Fas-mediated apoptosis and enhanced 
survival capacity. On the other hand, the up-regulated expre-
ssion of FasL in TEM upon T cell activation suggests that this 
subset is more sensitive to activation-induced cell death, as 
shown by the limited survival of these cells upon TCR trig-
gering, as well as by their enhanced sensitivity to Fas-induced 
cell death (Fig. 1, D and E; and Fig. 4 B).
Several kinases appear to be involved in FOXO3a phos-
phorylation, including IKK and AKT (32). In this paper, we 
show that IKKα∕β and AKT play critical roles in the phos-
phorylation of FOXO3a in TCM. Indeed, AKT and IKK 
  inhibitors not only prevent FOXO3a phosphorylation at S253, 
but also increase the expression of proapoptotic molecules 
such as Bim, leading to apoptosis. Moreover, we demon-
strated that pIKKα∕β levels are increased in TCM ex vivo as 
compared with TEM. This increased expression of activated 
IKK in TCM could lead to FOXO3a phosphorylation and the 
inhibition of its transcriptional activity. Because IKK also 
phosphorylates IκB (a negative regulator of NF-κB), it could 
also result in the activation of NF-κB, the major transcription 
factor of several survival genes, and therefore favor TCM cell 
survival (47). pAKT was undetectable ex vivo in both mem-
ory subsets. However, H2O2 or CD28 treatments lead to a 
more signifi  cant up-regulation of pAKT in TCM as compared 
with TEM. These results strongly suggest that TCM survival 
ability depends, in part, upon the activation of IKK and/or 
AKT, whereas reduced activities of AKT and/or IKKα∕β in JEM VOL. 204, January 22, 2007  89
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TEM lead to the inhibition of FOXO3a phosphorylation and 
the subsequent induction of the proapoptotic molecule Bim. 
These results concur with data obtained in Bim knockout 
mice showing that the absence of Bim leads to the expansion 
of memory cells (48).
Our results show that the induction of FOXO3a phos-
phorylation at S315 required both CD3 and CD28 engage-
ment, whereas T32 phosphorylation is dependent on γc 
cytokine (IL-2 and IL-7) triggering. Both AKT and IKK 
could be responsible for the phosphorylation of FOXO3a at 
S315 upon TCR/CD28 triggering. TCR signaling triggers 
the activation of NF-κB and IKK (49), and CD28 triggering 
enhances AKT phosphorylation (50). The phosphorylation 
of FOXO3a at T32 induced by IL-7 or IL-2 can be regulated 
by AKT, as Barata et al. shows that the activation of the 
  phosphatidylinositol 3–kinase–AKT axis is mandatory for the 
IL-7–mediated viability of T cells (51), and IL-2 triggering can 
also induce AKT activation (52). Moreover, we and others 
also have shown that IL-4 can induce T32 phosphorylation 
(unpublished data) (53).
To date, no mediator has been described as a unique 
  inducer of memory CD4+ T cell survival. As such, it is possible 
that multiple signals with redundant or partially overlapping 
functions could be involved to ensure the optimal survival of 
memory T cells. Our results suggest that cytokines and TCR/
CD3 signaling pathways converge to ensure distinct FOXO3a 
phosphorylation at T32 and S315, respectively. Thus, the 
combination of both signals could lead to higher levels of 
FOXO3a phosphorylated forms (quantitatively and qualita-
tively) and its subsequent inactivation, favoring the long-term 
survival of TCM. Our data provide a molecular mechanism for 
the observation reported by Seddon et al., who demonstrated 
that both IL-7 and CD3 engagement are involved in main-
taining homeostatic levels of TCM (10). The results described 
here improve our understanding of the molecular mecha-
nisms associated with TCM maintenance. The identifi  cation 
of these mechanisms is fundamental for deciphering the dys-
function of memory cells, which is often observed in several 
chronic diseases, including viral infections or tumors. They 
also pave the way for the development of strategies aimed at 
restoring the functionality of these cascades through the gen-
eration of immunotherapeutics that target these pathways, 
thereby promoting the establishment of a long-lived memory 
T cell pool.
MATERIALS AND METHODS
Reagents and antibodies. Recombinant human IL-2 was obtained trough 
the National Institutes of Health AIDS Reagent Depository. IL-7 and IL-4 
were purchased from R&D Systems. The kinase inhibitors AKT-IV, STO-
069, UO126, and wedelolactone were obtained from Calbiochem. Etopo-
side was purchased from Sigma-Aldrich. CH11 anti-FAS agonist antibodies 
were obtained from Immunotech. All antibodies for fl  ow cytometry were 
purchased from BD Biosciences, except for anti-CD45RA–ECD from 
Beckman Coulter and anti-CCR7–FITC from R&D Systems. Anti-
pFOXO3a S253, anti-pFOXO3a T32, anti-pan FOXO3a, anti-Bim, anti–
PIM-1, anti-pGab2 T452, anti-pIKKα∕β S176/180, and anti-pAKT 
S473–Alexa Fluor 488 were purchased from Cell Signaling Technology, 
Inc.; anti-FasL (5G51) was obtained from Qbiogene; anti-P130 (clone 
KAB40) was purchased from Sigma-Aldrich; anti-Gadd45a was obtained 
from Chemicon; and anti–PIM-2 and anti-pFOXO3a S315 were gifts 
from BD Biosciences. Horseradish peroxidase (HRP)–conjugated goat anti–
mouse and goat anti–rabbit IgG antibodies were obtained from Bio-Rad 
Laboratories. Anti–Rab-27a is a homemade antibody raised in rabbits against 
a GST-Rab-27 fusion protein.
Isolation of CD4+ T cell subpopulations. PBMCs from healthy subjects 
(provided by J.P. Routy and R. Boulassel, McGill University, Montreal, 
Canada) were isolated by a Ficoll-Hypaque (GE Healthcare) density gradi-
ent. All donors signed informed consent forms approved by the Royal Vic-
toria Hospital review board and the Centre de Recherche, CHUM. We fi  rst 
enriched for CD4+ T cells using negative immunomagnetic bead selection 
(autoMACS; Miltenyi Biotec). Cells were labeled with anti-CD4–APCcy7, 
anti-CD45RA–ECD, anti-CD27–FITC, and anti-CCR7–PEcy7 and sorted 
into naive, TCM, and TEM. Sorting was performed using a fl  ow cytometer 
(FACSAria; BD Biosciences). The purity of the TCM and TEM sub-popula-
tions ranged from 96 to 99%. All procedures were done at 4°C to minimize 
any changes in cell phenotype or gene expression.
RNA isolation, amplifi  cation, and microarray hybridization. Sample 
RNA was extracted using an RNA extraction kit (QIAGEN) and amplifi  ed 
using an RNA kit (MessageAmp; Ambion) according to the manufacturer’s 
instructions. The amplifi  ed RNA (aRNA) was verifi  ed for quality and quan-
tity using a bioanalyzer (model 2100; Agilent Technologies) and measuring 
the OD. All patient samples were hybridized against amplifi  ed  universal 
aRNA at 37°C for 18 h on a custom human immune array. Detailed informa-
tion on the labeling and hybridization procedures is available at http://www
.microarrays.ca. Experimental design, sample description and preparations, 
  hybridizations, data analysis, and annotations meet MIAME compliance.
Microarray data preprocessing. Microarrays were scanned at 16 bits 
  using the ScanArray Express (Packard Instrument Co.). The microarrays 
were then screened for quality, fi  rst by visual inspection of the array with 
fl  agging of poor quality spots and then with automated scripts that scanned 
the quantifi  ed output fi  les and measured overall density distribution on each 
channel and the number of fl  agged spots. Lowess normalization was then 
applied on the scanned chips. Microarray data is available in the National 
Center for Biotechnology Information Gene Expression Omnibus under 
accession no. GSE4741 and is titled “Convergence of TCR and cytokine 
signaling leads to FOXO3a phosphorylation and drives the survival of 
central memory CD4+ T cells.”
Selection of the top 100 TCM/TEM-discriminating genes. From the set 
of 19k microarray genes that passed quality control criteria during preprocess-
ing of microarray data, we retained only the genes that signifi  cantly discrimi-
nate TCM from TEM according to the F-test (P < 0.01). From this set, a fi  nal 
subset of 100 genes was further manually selected according to known func-
tions and pathways, including apoptosis, cell cycle, and signaling.
PCA. A data matrix comprising 13 TCM and 13 TEM samples (rows), and the 
100 top TCM/TEM-discriminating genes (see previous section) was con-
structed. Using singular value decomposition of the data matrix, a standard 
PCA of the data’s 100 × 100 covariance matrix was computed, with each 
sample comprising 100 genes. PCA was computed and plot generated by 
GeneLinker Platinum software (version 4.6; Improved Outcomes Software).
Two-way hierarchical clustering. Hierarchical clustering was performed 
over the same set of 26 samples and 100 genes as used for PCA. We used the 
Pearson correlation as the similarity measure between genes and samples for 
clustering. Analyses were performed using GeneLinker Platinum software.
Quantitative real-time PCR analysis. Changes in gene expression 
  observed by array analyses were verifi  ed by a low density array performed on 
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synthesized from total RNA (1 μg per sample) in an RT reaction in 20 μl 
of 1× fi   rst-strand synthesis buff   er (Invitrogen). Amplifi   cation of cDNA 
(1:20) was performed using SYBR Green PCR buff  er (PerkinElmer) con-
taining 0.1 μM of specifi  c primers. Before the samples were analyzed, stan-
dard curves of purifi  ed, target-specifi  c amplicons were created. The mRNA 
expression for each gene was determined by comparing it with its respective 
standard curve. This measurement was controlled for RNA quality, quan-
tity, and RT effi   ciency by normalizing it to the expression level of the 
GAPDH gene. Statistical signifi  cance was determined by use of normalized 
fold changes and ANOVA. The p-values were calculated using a two-tailed 
t test, assuming that the true variances were unknown.
Induction and quantifi  cation of apoptosis. Sorted cells were cultured in 
complete RPMI 1640 and treated as indicated in the fi  gure legends. Apoptotic 
cells were detected using Annexin V labeling according to the manufacturer’s 
protocol (Biosource International). The fl  uorescence signals were measured by 
fl  ow cytometry using a fl  ow cytometer (LSRI; BD Biosciences). Approxi-
mately 50,000 gated events were collected for each sample.
Western blotting analysis. TCM and TEM were sorted as described in Isola-
tion of CD4+ T cell subpopulations. Cells were washed twice with PBS and 
resuspended in lysis buff  er containing 50 mM NaF and 1 mM sodium pyro-
phosphate. 10 μg of proteins from total cell extracts were separated on SDS-
PAGE and electrotransfered onto polyvinylidene membranes (Roche). 
Membranes were incubated overnight at 4°C with specifi   c antibodies, as 
described in the fi  gure legends. Detection of the immune complexes was per-
formed using HRP-conjugated goat anti–mouse (1:2,500) or goat anti–rabbit 
(1:3,000) IgG antibodies. HRP activity was detected using an enhanced che-
miluminescence detection procedure (ECL Plus; GE Healthcare). Membranes 
were subsequently stripped and restained with an antiactin antibodies (1:10,000). 
The expression level of actin was used to control for equal loading. Protein 
  expression levels were expressed as a percentage of the highest signals obtained.
Intracellular staining. The cells were labeled with anti-CD4–AmCyan, 
anti-CD27–PB, and anti-CD45RA–APCcy7 for 20 min at 4°C. The cells 
were fi  xed in 2% paraformaldehyde for 15 min at room temperature and 
incubated with anti–Gr-B–Alexa Fluor 700, antiperforin-FITC, or anti- 
FasL–PE for 20 min at room temperature in 0.5% saponin (in PBS). Analysis 
was performed on gated TCM and TEM. Approximately 20,000 gated 
events were collected on a fl  ow cytometer (LSRII; BD Biosciences).
Proliferation assay. Sorted TCM or TEM were co-cultured with mDCs 
(T cell/DC ration = 40:1) in the presence of 50 ng/ml SEA. After 1–15 d 
of co-culture, cells were labeled with anti-CD4 and anti-TCRVβ22. For 
the analysis, cells were gated on CD4+ T cells, and  150,000-gated events 
were collected on an LSRII fl  ow cytometer.
Phosfl  ow analysis of STAT5a and AKT status. PBMCs were resus-
pended at 20 million cells/ml in RPMI 1640 and incubated for 30 min in 
the presence of CCR7-FITC antibodies (20 μl/million cells) at room tem-
perature. The cells were washed and resuspended at a cell concentration of 
5 million cells/ml in PBS and stimulated for 15 min at 37°C in the pres-
ence of 100 U/ml IL-2 or 10 ng/ml IL-7. After stimulation, the cells were 
fi  xed for 10 min at 37°C using Cytofi  x buff  er (BD Biosciences), pelleted, 
and permeabilized in PERM III buff  er (BD Biosciences) for 30 min on 
ice. The cells were washed twice in staining buff  er (BD Biosciences) and 
rehydrated for 30 min on ice in the staining buff  er. Cells were labeled 
with anti-CD4–APCcy7, anti-CD45RA–ECD, anti-CD27–PE, and anti-
pSTAT5a (Y694)–Alexa Fluor 647 specifi  c antibodies for 30 min at room 
temperature. For the analysis, the cells were gated on TCM and TEM. An 
average of 20,000 gated events was collected on an LSRII fl  ow cytometer. 
For CD28 cross-linking, the cells were resuspended at 10 million cells/ml 
in the presence of 2 μg/ml CD28 for 30 min on ice. The cells were 
washed twice in PBS and subsequently stimulated by cross-linking with 
20 μg/ml rabbit anti–mouse Igs (Biosource International) in 25 μl of 
  prewarmed medium for 15 min. The cells were fi  xed and permeabilized as 
described and labeled with CD4-APCcy7, CD45RA-ECD, CD27-PE, 
and pAKT S473–Alexa Fluor 488. Flow cytometry analysis was performed 
on gated TCM and TEM. Approximately 20,000-gated events were collected 
on an LSRII fl  ow cytometer.
Online supplemental material. Table S1 shows a complete list of genes 
that are diff  erentially expressed in TCM and TEM. Fig. S1 A shows the induc-
tion of STAT-5a phosphorylation in TTM. Fig. S1 B shows real-time RT-
PCR in TCM, TEM, and TTM subsets. Fig. S2 shows histograms of Phosfl  ow 
analysis of AKT phosphorylation after treatment with H2O2. Fig. S3 is a 
proposed model showing how signaling through TCR and cytokines induce 
survival of TCM. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20061681/DC1.
We thank Eric Massicotte for cell sorting, Marc Vendette for technical assistance, 
Jean-Pierre Routy and Rachid Boulassel for providing blood samples, and Abdelkader 
Yachou for administrative support. We also thank Nicolas Chomont, Alain Dumont, 
Jim Woodgett, and Sylvain Meloche for critically reviewing the manuscript.
This study was supported by funds from the National Institutes of Health, 
the Canadian Institutes of Health Research, Genome Quebec, Genome Canada, 
Fonds de Recherche en santé du Québec, and the Canadian Network for Vaccines 
and Immunotherapeutics. R.-P. Sekaly is the Canada Research Chair in 
Human Immunology.
The authors have no confl  icting fi  nancial interests.
Submitted: 7 August 2006
Accepted: 29 November 2006
R  E  F  E  R  E  N  C  E  S 
  1.  Kaech, S.M., E.J. Wherry, and R. Ahmed. 2002. Eff  ector and memory 
T-cell diff  erentiation: implications for vaccine development. Nat. Rev. 
Immunol. 2:251–262.
  2.  Sallusto, F., J. Geginat, and A. Lanzavecchia. 2004. Central memory and 
eff  ector memory T cell subsets: function, generation, and maintenance. 
Annu. Rev. Immunol. 22:745–763.
  3.  Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. 
Two subsets of memory T lymphocytes with distinct homing potentials 
and eff  ector functions. Nature. 401:708–712.
  4.  Fritsch, R.D., X. Shen, G.P. Sims, K.S. Hathcock, R.J. Hodes, and P.E. 
Lipsky. 2005. Stepwise diff  erentiation of CD4 memory T cells defi  ned 
by expression of CCR7 and CD27. J. Immunol. 175:6489–6497.
 5. Wu, C.Y., J.R. Kirman, M.J. Rotte, D.F. Davey, S.P. Perfetto, E.G. 
Rhee, B.L. Freidag, B.J. Hill, D.C. Douek, and R.A. Seder. 2002. 
Distinct lineages of T(H)1 cells have diff  erential capacities for memory 
cell generation in vivo. Nat. Immunol. 3:852–858.
 6. Zaph, C., J. Uzonna, S.M. Beverley, and P. Scott. 2004. Central 
memory T cells mediate long-term immunity to Leishmania major in the 
  absence of persistent parasites. Nat. Med. 10:1104–1110.
 7. Letvin, N.L., J.R. Mascola, Y. Sun, D.A. Gorgone, A.P. Buzby, L. 
Xu, Z.Y. Yang, B. Chakrabarti, S.S. Rao, J.E. Schmitz, et al. 2006. 
Preserved CD4+ central memory T cells and survival in vaccinated 
SIV-challenged monkeys. Science. 312:1530–1533.
 8. Sad, S., and L. Krishnan. 2003. Maintenance and attrition of T-cell 
memory. Crit. Rev. Immunol. 23:129–147.
 9. Macallan, D.C., D. Wallace, Y. Zhang, C. De Lara, A.T. Worth, H. 
Ghattas, G.E. Griffi   n, P.C. Beverley, and D.F. Tough. 2004. Rapid 
turnover of eff  ector–memory CD4+ T cells in healthy humans. J. Exp. 
Med. 200:255–260.
10. Seddon, B., P. Tomlinson, and R. Zamoyska. 2003. Interleukin 7 and 
T cell receptor signals regulate homeostasis of CD4 memory cells. Nat. 
Immunol. 4:680–686.
11. Kondrack, R.M., J. Harbertson, J.T. Tan, M.E. McBreen, C.D. Surh, 
and L.M. Bradley. 2003. Interleukin 7 regulates the survival and 
generation of memory CD4 cells. J. Exp. Med. 198:1797–1806.
12.  Patke, D.S., and D.L. Farber. 2005. Modulation of memory CD4 
T cell function and survival potential by altering the strength of the 
recall stimulus. J. Immunol. 174:5433–5443.JEM VOL. 204, January 22, 2007  91
ARTICLE
13. Kassiotis, G., R. Zamoyska, and B. Stockinger. 2003. Involvement of 
avidity for major histocompatibility complex in homeostasis of naive 
and memory T cells. J. Exp. Med. 197:1007–1016.
14.  Seder, R.A., and R. Ahmed. 2003. Similarities and diff  erences in CD4+ 
and CD8+ eff   ector and memory T cell generation. Nat. Immunol. 
4:835–842.
15. Haddad, E.K., X. Wu, J.A. Hammer III, and P.A. Henkart. 2001. 
Defective granule exocytosis in Rab27a-defi   cient lymphocytes from 
Ashen mice. J. Cell Biol. 152:835–842.
16.  Hitoshi, Y., J. Lorens, S.I. Kitada, J. Fisher, M. LaBarge, H.Z. Ring, U. 
Francke, J.C. Reed, S. Kinoshita, and G.P. Nolan. 1998. Toso, a cell 
surface, specifi  c regulator of Fas-induced apoptosis in T cells. Immunity. 
8:461–471.
17.  Yan, B., M. Zemskova, S. Holder, V. Chin, A. Kraft, P.J. Koskinen, and 
M. Lilly. 2003. The PIM-2 kinase phosphorylates BAD on serine 112 and 
reverses BAD-induced cell death. J. Biol. Chem. 278:45358–45367.
18. Gravestein, L.A., D. Amsen, M. Boes, C.R. Calvo, A.M. Kruisbeek, 
and J. Borst. 1998. The TNF receptor family member CD27 signals to 
Jun N-terminal kinase via Traf-2. Eur. J. Immunol. 28:2208–2216.
19. Grossmann, M., L.A. O’Reilly, R. Gugasyan, A. Strasser, J.M. Adams, 
and S. Gerondakis. 2000. The anti-apoptotic activities of Rel and RelA 
required during B-cell maturation involve the regulation of Bcl-2 
  expression. EMBO J. 19:6351–6360.
20.  Hao, Y., K. Sekine, A. Kawabata, H. Nakamura, T. Ishioka, H. Ohata, 
R. Katayama, C. Hashimoto, X. Zhang, T. Noda, et al. 2004. Apollon 
ubiquitinates SMAC and caspase-9, and has an essential cytoprotection 
function. Nat. Cell Biol. 6:849–860.
21. Hahn, H.P., M. Pang, J. He, J.D. Hernandez, R.Y. Yang, L.Y. Li, 
X. Wang, F.T. Liu, and L.G. Baum. 2004. Galectin-1 induces nuclear 
translocation of endonuclease G in caspase- and cytochrome c-independent 
T cell death. Cell Death Diff  er. 11:1277–1286.
22.  Shannan, B., M. Seifert, K. Leskov, J. Willis, D. Boothman, W. Tilgen, 
and J. Reichrath. 2006. Challenge and promise: roles for clusterin in patho-
genesis, progression and therapy of cancer. Cell Death Diff  er. 13:12–19.
23.  Wakasugi, K., and P. Schimmel. 1999. Two distinct cytokines released 
from a human aminoacyl-tRNA synthetase. Science. 284:147–151.
24.  Feng, X.H., and R. Derynck. 2005. Specifi  city and versatility in TGF-β 
signaling through Smads. Annu. Rev. Cell Dev. Biol. 21:659–693.
25. Essafi  , A., S. Fernandez de Mattos, Y.A. Hassen, I. Soeiro, G.J. Mufti, 
N.S. Thomas, R.H. Medema, and E.W. Lam. 2005. Direct transcrip-
tional regulation of Bim by FoxO3a mediates STI571-induced apoptosis 
in Bcr-Abl-expressing cells. Oncogene. 24:2317–2329.
26. Suhara, T., H.S. Kim, L.A. Kirshenbaum, and K. Walsh. 2002. 
Suppression of Akt signaling induces Fas ligand expression: involvement 
of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. 
Mol. Cell. Biol. 22:680–691.
27. Tran, H., A. Brunet, J.M. Grenier, S.R. Datta, A.J. Fornace Jr., P.S. 
DiStefano, L.W. Chiang, and M.E. Greenberg. 2002. DNA repair path-
way stimulated by the forkhead transcription factor FOXO3a through 
the Gadd45 protein. Science. 296:530–534.
28. Kops, G.J., R.H. Medema, J. Glassford, M.A. Essers, P.F. Dijkers, P.J. 
Coff  er, E.W. Lam, and B.M. Burgering. 2002. Control of cell cycle exit 
and entry by protein kinase B-regulated forkhead transcription factors. 
Mol. Cell. Biol. 22:2025–2036.
29. Morcinek, J.C., C. Weisser, E. Geissinger, M. Schartl, and C. 
Wellbrock. 2002. Activation of STAT5 triggers proliferation and con-
tributes to anti-apoptotic signalling mediated by the oncogenic Xmrk 
kinase. Oncogene. 21:1668–1678.
30. Nosaka, T., T. Kawashima, K. Misawa, K. Ikuta, A.L. Mui, and T. 
Kitamura. 1999. STAT5 as a molecular regulator of proliferation, diff  er-
entiation and apoptosis in hematopoietic cells. EMBO J. 18:4754–4765.
31. Willinger, T., T. Freeman, H. Hasegawa, A.J. McMichael, and M.F. 
Callan. 2005. Molecular signatures distinguish human central memory 
from eff  ector memory CD8 T cell subsets. J. Immunol. 175:5895–5903.
32. Coff  er, P.J., and B.M. Burgering. 2004. Forkhead-box transcription fac-
tors and their role in the immune system. Nat. Rev. Immunol. 4:889–899.
33. Van Der Heide, L.P., M.F. Hoekman, and M.P. Smidt. 2004. The ins 
and outs of FoxO shuttling: mechanisms of FoxO translocation and 
transcriptional regulation. Biochem. J. 380:297–309.
34.  Medema, R.H., G.J. Kops, J.L. Bos, and B.M. Burgering. 2000. AFX-
like Forkhead transcription factors mediate cell-cycle regulation by Ras 
and PKB through p27kip1. Nature. 404:782–787.
35. Hu, M.C., D.F. Lee, W. Xia, L.S. Golfman, F. Ou-Yang, J.Y. Yang, 
Y. Zou, S. Bao, N. Hanada, H. Saso, et al. 2004. IkappaB kinase 
  promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell. 
117:225–237.
36. Soderling, T.R. 1999. The Ca-calmodulin-dependent protein kinase 
cascade. Trends Biochem. Sci. 24:232–236.
37. Brunet, A., A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. 
Anderson, K.C. Arden, J. Blenis, and M.E. Greenberg. 1999. Akt pro-
motes cell survival by phosphorylating and inhibiting a Forkhead tran-
scription factor. Cell. 96:857–868.
38. You, H., M. Pellegrini, K. Tsuchihara, K. Yamamoto, G. Hacker, M. 
Erlacher, A. Villunger, and T.W. Mak. 2006. FOXO3a-dependent 
regulation of Puma in response to cytokine/growth factor withdrawal. 
J. Exp. Med. 203:1657–1663.
39. Murali-Krishna, K., L.L. Lau, S. Sambhara, F. Lemonnier, J. Altman, 
and R. Ahmed. 1999. Persistence of memory CD8 T cells in MHC class 
I-defi  cient mice. Science. 286:1377–1381.
40.  Swain, S.L., H. Hu, and G. Huston. 1999. Class II-independent genera-
tion of CD4 memory T cells from eff  ectors. Science. 286:1381–1383.
41. Dooms, H., E. Kahn, B. Knoechel, and A.K. Abbas. 2004. IL-2 in-
duces a competitive survival advantage in T lymphocytes. J. Immunol. 
172:5973–5979.
42. Holmes, S., M. He, T. Xu, and P.P. Lee. 2005. Memory T cells have 
gene expression patterns intermediate between naive and eff  ector. Proc. 
Natl. Acad. Sci. USA. 102:5519–5523.
43. Chtanova, T., R. Newton, S.M. Liu, L. Weininger, T.R. Young, 
D.G. Silva, F. Bertoni, A. Rinaldi, S. Chappaz, F. Sallusto, et al. 2005. 
Identifi  cation of T cell-restricted genes, and signatures for diff  erent T 
cell responses, using a comprehensive collection of microarray datasets. 
J. Immunol. 175:7837–7847.
44.  Schiott, A., M. Lindstedt, B. Johansson-Lindbom, E. Roggen, and C.A. 
Borrebaeck. 2004. CD27− CD4+ memory T cells defi  ne a diff  erenti-
ated memory population at both the functional and transcriptional levels. 
Immunology. 113:363–370.
45. Sunters, A., S. Fernandez de Mattos, M. Stahl, J.J. Brosens, G. 
Zoumpoulidou, C.A. Saunders, P.J. Coff   er, R.H. Medema, R.C. 
Coombes, and E.W. Lam. 2003. FoxO3a transcriptional regulation 
of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. 
J. Biol. Chem. 278:49795–49805.
46. Jonsson, H., P. Allen, and S.L. Peng. 2005. Infl  ammatory  arthritis 
  requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. 
Nat. Med. 11:666–671.
47.  Siebenlist, U., K. Brown, and E. Claudio. 2005. Control of lymphocyte 
development by nuclear factor-kappaB. Nat. Rev. Immunol. 5:435–445.
48. Wojciechowski, S., M.B. Jordan, Y. Zhu, J. White, A.J. Zajac, and 
D.A. Hildeman. 2006. Bim mediates apoptosis of CD127(lo) eff  ector 
T cells and limits T cell memory. Eur. J. Immunol. 36:1694–1706.
49.  Weil, R., K. Schwamborn, A. Alcover, C. Bessia, V. Di Bartolo, and A. 
Israel. 2003. Induction of the NF-kappaB cascade by recruitment of the 
scaff  old molecule NEMO to the T cell receptor. Immunity. 18:13–26.
50. Appleman, L.J., A.A. van Puijenbroek, K.M. Shu, L.M. Nadler, and 
V.A. Boussiotis. 2002. CD28 costimulation mediates down-regulation 
of p27kip1 and cell cycle progression by activation of the PI3K/PKB sig-
naling pathway in primary human T cells. J. Immunol. 168:2729–2736.
51. Barata, J.T., A. Silva, J.G. Brandao, L.M. Nadler, A.A. Cardoso, and 
V.A. Boussiotis. 2004. Activation of PI3K is indispensable for interleu-
kin 7–mediated viability, proliferation, glucose use, and growth of T cell 
acute lymphoblastic leukemia cells. J. Exp. Med. 200:659–669.
52.  Kelly, E., A. Won, Y. Refaeli, and L. Van Parijs. 2002. IL-2 and related 
cytokines can promote T cell survival by activating AKT. J. Immunol. 
168:597–603.
53. Bilancio, A., K. Okkenhaug, M. Camps, J.L. Emery, T. Ruckle, C. 
Rommel, and B. Vanhaesebroeck. 2006. Key role of the p110delta iso-
form of PI3K in B-cell antigen and IL-4 receptor signaling: comparative 
analysis of genetic and pharmacologic interference with p110delta func-
tion in B cells. Blood. 107:642–650.